The global market for GLP-1 drugs is expected to experience significant growth, with various projections indicating it will reach tens of billions of dollars by 2030 or 2035. The demand for GLP-1 treatments, particularly oral obesity therapies, is driving this growth, although some reports suggest that individual companies may experience varying levels of success. The market's exact size and growth rate are uncertain, with different outlets providing different estimates, ranging from $6.32 billion by 2030 to over $70 billion by 2035.